CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 5,652 enrolled
Drug / intervention
insulin detemirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00264901
NCT00264901Phase 4Completed
CompareCT.gov

Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir® (Insulin Detemir [rDNA Origin] Injection) (PREDICTIVE™ 303)

Novo Nordisk A/S·interventional·Posted Dec 13, 2005·Updated Jan 31, 2017

In Brief

A Phase 4 clinical trial evaluating insulin detemir for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 5,652 participants across 1 site.

Detailed Summary

This trial is conducted in the United States of America (USA). This trial aims for a comparison of the safety and efficacy in subjects with type 2 diabetes using either self titration or physician guided titration according to the local standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 13, 2005
Enrollment StartOct 1, 2005
Primary CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.6 years ago

Interventions

insulin detemirdrug